Novartis Pharmaceuticals

About Novartis Pharmaceuticals

Novartis Pharmaceuticals sits in Radiopharma Developer, a segment Bracken sees as structurally important to the radiopharma value chain.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• Reuters Health · 2026-01-16
  Novartis Pharmaceuticals expands cyclotron capacity to meet Lu-177 demand
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Endpoints News · 2026-02-07
  Novartis Pharmaceuticals announces Phase II readout for lead theranostic candidate
  The announcement comes amid tightening Mo-99 and Lu-177 supply.
• FierceBiotech · 2026-11-18
  Novartis Pharmaceuticals appoints new Chief Medical Officer ahead of pivotal trial
  The work builds on more than a decade of radiochemistry collaboration.
• BioPharma Reporter · 2026-08-25
  Novartis Pharmaceuticals signs supply agreement to support late-stage trials
  The work builds on more than a decade of radiochemistry collaboration.
• Imaging Wire · 2026-05-04
  Novartis Pharmaceuticals closes Series C round to scale radiopharma manufacturing
  The announcement comes amid tightening Mo-99 and Lu-177 supply.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.